A quantitative assessment of patient barriers to insulin

International Journal of Clinical Practice

Volumn 65, Issue 4, 2011, Pages 408-414

  Casciano, R ^a   Malangone, Elisabetta ^a   Ramachandran, A ^b   Gagliardino, J J ^c  

^a Analytica International   (United States)

^b Dr A Ramachandran's Diabetes Hospitals   (India)

^c University of La Plata CONICET   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISCRETE CHOICE MODELING; DRUG USE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT PREFERENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL MODEL;

ADULT; AGED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUESTIONNAIRES; YOUNG ADULT;

EID: 79952768935     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02590.x     Document Type: Article

References (21)

1. Daneman D. Type 1 diabetes. Lancet 2006; 367: 847-58. (Pubitemid 43363372)
2. Diagnosis of Diabetes. 2008. http://www.diabetes.niddk.nih.gov/dm/pubs/ diagnosis/index.html (accessed December 2009).
3. Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab 2009; 35: 77-84.
4. Campbell RK. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc (2003) 2009; 49(Suppl. 1): S3-9.
5. Fact sheet No 312. Diabetes. 2009. http://www.who.int/mediacentre/ factsheets/fs312/en/print.html (accessed December 2009).
6. Diabetes and Impaired Glucose Tolerance: Global Burden: Prevalence and Projections, 2010 and 2030. Diabetes Atlas 2009; fourth. http://www. diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance (accessed December 2009).
7. Regional overview: Africa. Diabetes Atlas 2009; fourth. http://www.diabetesatlas.org/content/africa (accessed December 2009).
8. Regional Overview: Middle East and North Africa. Diabetes Atlas 2009; fourth http://www.diabetesatlas.org/content/middle-east-and-north-africa (accessed December 2009).
9. Regional Overview: South and Central America. Diabetes Atlas 2009; fourth. http://www.diabetesatlas.org/content/south-and-central-america (accessed December 2009).
10. Regional Overview: South-East Asia. Diabetes Atlas 2009; fourth. http://www.diabetesatlas.org/content/south-east-asia (accessed December 2009).
11. Regional Overview: Western Pacific. Diabetes Atlas 2009. http://www.diabetesatlas.org/content/western-pacific (accessed December 2009).
12. Regional Overview: North America and Caribbean. Diabetes Atlas 2009. http://www.diabetesatlas.org/content/north-america-and-caribbean (accessed December 2009).
13. Diabetes Atlas. Prevalence estimates of diabetes mellitus (DM), 2010. http://www.diabetesatlas.org/content/prevalence-estimatesdiabetes-mellitus-dm- 2010 (accessed December 2009).
14. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005; 27: 1500-12. (Pubitemid 41739488)
15. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
16. Chancellor J, Aballea S, Lawrence A et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008; 26: 217-34. (Pubitemid 351271380)
17. Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28: 427-8. (Pubitemid 40170954)
18. Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol 2010; 25: 1207-17.
19. Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice experiments to elicit preferences. Qual Health Care 2001; 10(Suppl. 1): i55-60.
20. SAS, Institute, Inc. SAS, 9.1th edn. Cary, NC: SAS Institute Inc, 2002-2004.
21. Hwa YS. Conjoint analysis: an application in eliciting patients' preferences. Bull Malays Math Sci Soc 2006; 2: 187-201.